在多发性硬化症的不同治疗策略中使用ocrelizumab:为期5年的基于人口的研究
Marcello Moccia1,2, Giuseppina Affinito3, Giuseppina Marrazzo4
1Multiple Sclerosis Unit, Policlinico Federico II University Hospital, Via Sergio Pansini 5, 80131 Naples, Italy.
Neurology international
|April 26, 2024
概括
与其他多发性硬化症 (MS) 治疗相比,ocrelizumab表现出更好的持久性和坚持性. 对现实世界的数据的分析表明,在MS治疗中,ocrelizumab的益处风险概况和成本效益是有利的.
科学领域:
- 神经学 神经学
- 药物经济学 药物经济学
- 现实世界的证据.
背景情况:
- 关于多发性硬化症 (MS) 治疗的现实数据对于了解长期结果至关重要.
- 将ocrelizumab与其他疾病修饰治疗 (DMT) 进行比较,可以了解持续性,坚持性,医疗保健利用率和成本.
研究的目的:
- 评估现实世界中的持续性,坚持性,医疗保健资源利用率和ocrelizumab与其他DMT在MS患者中的成本.
- 为了比较DMT序列及其对患者结果和医疗保健经济学的影响.
主要方法:
- 从2018年1月到2022年12月,在意大利坎帕尼亚,对3371名多发性硬化症患者进行了回顾性分析.
- 数据来源包括医院出院记录,药物处方和豁免代码.
- 关键指标:持久性,依从性覆盖日数 (PDC) 的比例,DMT成本,与MS相关的住院费用.
主要成果:
- 经常处方ocrelizumab (n=682),其中28.8%的患者从未使用过DMT.
- 与其他高活性和低/中效的DMT相比,ocrelizumab的中止风险显著降低,坚持更高.
- 对于ocrelizumab,每月的DMT成本低于其他高活性DMT,但高于低/中效DMT.
结论:
- 在临床实践中,ocrelizumab是一种相关的DMT,经常被处方给发生的MS患者.
- 这种药物与最高的持久性和坚持性有关,这表明它具有有利的利益风险概况.
- 发现ocrelizumab的成本低于其他高活性DMT的成本.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...